Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lupin Limited ( (IN:LUPIN) ) has issued an update.
Lupin Limited said the U.S. Food and Drug Administration has completed an inspection of its Ankleshwar manufacturing facility in India, conducted from March 2 to March 7, 2026. The review closed with a Form 483 containing two observations, indicating issues the regulator expects the company to remediate.
Lupin plans to address the U.S. FDA’s observations and submit a response within the required timeframe, reaffirming its commitment to CGMP compliance across all sites. While the presence of observations signals some gaps in quality or processes, the limited number may help reassure investors and partners that the facility remains broadly aligned with regulatory expectations.
More about Lupin Limited
Lupin Limited is an India-based pharmaceutical company focused on manufacturing generic and specialty medicines for global markets, including the highly regulated U.S. market. The company operates multiple facilities across India and emphasizes compliance with current Good Manufacturing Practice (CGMP) standards to support its international supply footprint.
Average Trading Volume: 34,321
Technical Sentiment Signal: Buy
Current Market Cap: 1066B INR
See more insights into LUPIN stock on TipRanks’ Stock Analysis page.